- Details
- Description
-
Packaging Size30T*25mg/bottle
-
Strength30T
-
CompositonTenofovir Alafenamide,TAF
-
TreatmentHBV,HIV,AIDS
-
FormTablets
-
BrandPhotafe
-
Quantity Unit25mg*30T/bottle
-
ManufacturerPHOKHAM 2 PHARMACEUTICAL,LAOs PDR
Tenofovir alafenamide, sold under the brand name Photafe25, Vemlidy, is a hepatitis B virus (HBV) nucleotide reverse transcriptase inhibitor medication for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.It is taken by mouth.
Tenofovir alafenamide is a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan for use in the treatment of HIV/AIDS and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016.
